Literature DB >> 2775256

Secretion of transferrin by human breast cancer cells.

B Vandewalle1, L Hornez, F Revillion, J Lefebvre.   

Abstract

Transferrin (Tf), the major iron-binding protein in the plasma of vertebrate species is an essential growth factor for cells in serum-free media and appears to be involved in the regulation of growth and differentiation of human tissues. We report here that human breast cancer cells secrete a factor immunologically similar to Tf. The secretion of Tf by the hormone-responsive cell-line MCF-7 is stimulated by 17 beta-estradiol and reduced by the antiestrogen 4-hydroxy tamoxifen. These data suggest that Tf secreted by breast cancer cells may be an additional autocrine growth factor confering selective advantages to rapidly proliferating breast cancer cells and perhaps permit tumor cell growth in poorly vascularized areas.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2775256     DOI: 10.1016/0006-291x(89)92112-8

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  4 in total

1.  Identification of transferrin and inhibin-like proteins in matrigel.

Authors:  G Dirami; V Papadopoulos; H K Kleinman; D C Defreese; N A Musto; M Dym
Journal:  In Vitro Cell Dev Biol Anim       Date:  1995-06       Impact factor: 2.416

2.  Autocrine growth induced by transferrin-like substance in bladder carcinoma cells.

Authors:  H Tanoguchi; M Tachibana; M Murai
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

3.  Protein Corona Gold Nanoparticles Fingerprinting Reveals a Profile of Blood Coagulation Proteins in the Serum of HER2-Overexpressing Breast Cancer Patients.

Authors:  María Del Pilar Chantada-Vázquez; Antonio Castro López; María García-Vence; Benigno Acea-Nebril; Susana B Bravo; Cristina Núñez
Journal:  Int J Mol Sci       Date:  2020-11-10       Impact factor: 5.923

4.  Quantitative analysis of the anti-proliferative activity of combinations of selected iron-chelating agents and clinically used anti-neoplastic drugs.

Authors:  Eliska Potuckova; Hana Jansova; Miloslav Machacek; Anna Vavrova; Pavlina Haskova; Lucie Tichotova; Vera Richardson; Danuta S Kalinowski; Des R Richardson; Tomas Simunek
Journal:  PLoS One       Date:  2014-02-20       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.